Another new British crown vaccine starts human trials

(Fighting against New Coronary Pneumonia) Another new British Crown vaccine starts human trials

　　China News Agency, London, June 25 (Zhao Xingyiping) The Imperial College of Science and Technology research team announced to the outside world on the 24th that the new crown vaccine it developed began to be vaccinated on volunteers that day. This is another new crown vaccine that entered this stage after the vaccine developed by Oxford University in England entered the human trial stage in April.

　　Robin Shattock, a professor at Imperial College London, said the vaccine has completed the previous phase of animal testing. The test results show that the vaccine is safe and can trigger an effective immune response. About 300 volunteers will be vaccinated in the next few weeks. The next phase of human trials is planned for October, and the number of vaccinators will be expanded to 6,000.

　　Shatok said that the vaccine development is based on a new method that uses a synthetic genetic chain called RNA to mimic the new coronavirus. Once the vaccine is injected into the human muscle, the RNA will replicate itself, instructing the body's own cells to replicate the virus's external spike protein, prompting the immune system to recognize and fight the new coronavirus, thereby avoiding human infection.

　　Dr. Katrina Pollock, the principal investigator who led the study and an infectious disease expert at Imperial College London, said he was "cautiously optimistic" about the results of human trials.

　　Shatok said, "We have been able to produce vaccines from scratch and conduct human trials in just a few months." "If our methods are effective, vaccines can provide effective protection for people and may completely change our future response. The way of the new coronavirus epidemic."

　　The research by the Imperial College of England has received £41 million in funding from the British government and £5 million in social donations. The research team hopes that from the beginning of 2021, the vaccine can be distributed in the UK and overseas. (Finish)